Immunotoxin Therapy in Treating Patients With Advanced Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed malignancy, including one of the following:
• •* Malignant mesothelioma
• •* Ovarian epithelial carcinoma (mucinous or nonmucinous), including primary peritoneal or fallopian tube carcinoma
• •* Tumors that may have originated in the bowel (e.g., appendiceal carcinoma) and involve the ovary
• •* Ovarian cancers of other histology are eligible provided they express mesothelin
• •* Pancreatic cancer
• •* Squamous cell lung cancer
• •* Squamous cell cancer of the head and neck
• •* Squamous cell cancer of the cervix
• •Recurrent unresectable disease after prior standard anticancer therapy that was expected to prolong survival and improve quality of life OR unwilling to receive standard anticancer therapy
• •At least 30% of initial or recurrent tumor cells positive (at least 1+) for mesothelin by immunohistochemistry
• •Measurable or evaluable disease
• •No known CNS or spinal cord involvement
• •No clinically significant pericardial effusion
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 12 weeks
• •Hematopoietic:
• •Absolute neutrophil count at least 1,000/mm\^3
• •Platelet count at least 75,000/mm\^3
• •Hepatic:
• •Bilirubin no greater than upper limit of normal (ULN)
• •AST and ALT no greater than 2.5 times ULN
• •Albumin at least 3.0 g/dL
• •Hepatitis B and C negative
• •Renal:
• •Creatinine no greater than ULN OR
• •Creatinine no greater than 2.0 mg/dL if creatinine clearance at least 50 mL/min
• •Calcium no greater than ULN
• •Cardiovascular:
• •No New York Heart Association class II-IV heart disease
• •Pulmonary:
• •Oxygen saturation (SO\_2) more than 92% on room air
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •HIV negative
• •No detectable antibody to SS1(dsFv)-PE38
• •No infection requiring parenteral antibiotics
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 1 week since prior hematopoietic growth factor therapy
• •Chemotherapy:
• •Not specified
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •Not specified
• •Surgery:
• •Not specified
• •Other:
• •At least 4 weeks since any prior antitumor therapy and recovered
• •No other concurrent antitumor therapy